Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UCLA
Dates
study started
completion around

Description

Summary

The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation.

Official Title

A Phase 1, Open-Label, Multicenter Study of INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

Keywords

Solid Tumors, INCB186748, KRASG12D Mutation, pancreatic ductal adenocarcinoma (PDAC), colorectal cancer (CRC), Neoplasms, Cetuximab, GEMNabP, mFOLFIRINOX, Food-Effect

Eligibility

Locations

  • UCLA Healthcare Hematology-Oncology not yet accepting patients
    Santa Monica California 90404 United States
  • Sarah Cannon Research Institue At Healthone accepting new patients
    Denver Colorado 80218 United States
  • Scri Oncology Partners accepting new patients
    Nashville Tennessee 37203 United States

Details

Status
accepting new patients at some sites,
but this study is not currently recruiting here
Start Date
Completion Date
(estimated)
Sponsor
Incyte Corporation
Links
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
ID
NCT06818812
Phase
Phase 1 research study
Study Type
Interventional
Participants
Expecting 308 study participants
Last Updated